Formation Bio
@formationbio
Followers
2K
Following
88
Media
53
Statuses
133
AI-native pharma company, bringing new treatments to patients faster and more efficiently.
New York, NY
Joined November 2014
@IMIDomics discovered the initial science, and now @formationbio is taking it forward to clinical development. Today we announced our license of IMIDomics' first-in-class, Phase-1 ready anti-CD226 antibody targeting Ulcerative Colitis. Go behind the scenes with both teams here.
0
4
13
New on the blog: how Formation Bio’s drug canvassing system uncovers “dark” or deprioritized assets, turning overlooked data into concrete signals for our BD team. Read the full piece here: https://t.co/p862O1Oh70
0
4
5
Next week, a few of our team will be at @PHUSE_Global EU Connect in Hamburg to share insights on how AI systems in our tech stack enhance clinical decision-making and streamline drug development. Learn more here: https://t.co/Jy7ou2rmua
0
0
0
Honored to be named R&D Platform of the Year by @BioTech_Awards. Our AI-native platform is accelerating the development of new medicines for patients. Learn more about our work here:
formation.bio
1
0
1
Proud to see @BenjamineYLiu recognized in @BioSpace’s 40 Under 40 this year! Read the full write-up here:
biospace.com
Formation Bio
0
2
4
Our CDO @gavincorcoranmd will be representing Formation Bio at @FierceBiotech Week on October 9! Read more here: https://t.co/0Hej0J7xxH Gavin will join other panelists from: @sagimet, @NautilusBio, @TakedaOncology, Alkahest, Inc (@sclohr)
0
0
0
Formation Bio has been named a Fierce 15 Biotech Company of 2025! @FierceBiotech recognized us as one of the most innovative biotechs for our AI-native approach to radically more efficient drug development. More shots on goal → more medicines for patients https://t.co/tTiThpfE1F
fiercebiotech.com
From advancing radically new therapies to refining existing modalities, this year’s Fierce 15 companies are pushing the envelope and giving us a reason for optimism.This year has been chock-full of...
0
2
7
Thrilled to welcome Lou Brenner (CMO), Danny Neil (CTO), Frank D'Amelio (Sr. Advisor) and Dash Dhanak (Sr. Advisor) to @formationbio as our newest senior leaders. With decades of experience at Pfizer, BenevolentAI, Incyte, Janssen, GSK & more, they’ll help us scale our
formation.bio
Former Pfizer, BenevolentAI, Incyte, and AMAG executives join to strengthen clinical, technology, financial, and scientific leadership as company scales its AI-native pharma model
1
0
5
Coming up next week in SF: @formationbio Co-Founder & CEO @BenjamineYLiu will be speaking at @EricNewcomer's AI Health & Longevity Summit, where he'll be discussing all things AI + drug development.
0
4
10
Proud to see our Co-Founder & CEO @BenjamineYLiu on this list! If you're based in NYC, Boston, SF/Bay Area, or the Research Triangle (NC) and interested in joining our team -- check out our open roles: https://t.co/pW8Ry8cpsk
https://t.co/cC2oPgEqXe
thegreatentrepreneurs.com
Great Entrepreneurs is pleased to announce The Top 25 HealthTech Entrepreneurs of New York for 2025. Based in one of the country’s most active centers for healthcare, life sciences, and venture-bac...
0
0
1
Great to see our transaction with @IMIDomics covered by @AndrewE_Dunn in @endpts. This is a promising step forward in autoimmune therapy for a patient population with high unmet need. Read more here!
Exclusive: Formation Bio raised a $372M Series D last year. Later today, the New York biopharma will announce its first licensing deal since raising that money — bringing in a CD226 antibody from the Spanish biotech IMIDomics. My latest for @endpts:
0
1
5
If you’re building for 10+ years, “just get started” won’t cut it. @BenjamineYLiu (CEO/cofounder of @formationbio ) says: ask the counterfactual. Would the world be any different if your company didn’t exist? If not, go back to the whiteboard.
1
3
11
This morning we announced the license of gusacitinib, a dual JAK/SYK inhibitor, to Sanofi! We are excited that this transaction with Sanofi ushers gusacitinib into its next stage of development. You can read more here: https://t.co/7Srj1McuM6
prnewswire.com
/PRNewswire/ -- Formation Bio, an AI-native pharma company focused on accelerating drug development, today announced that its subsidiary Libertas Bio has...
0
0
2
The future of drug development is AI-native, and we're leading the charge. Hear more from our Co-Founder & CEO @BenjamineYLiu on @CNBC @CNBCFastMoney
https://t.co/AF07oJG2uG
1
1
2
Excited to be named to @CNBCDisruptors 50 List this year. As AI disrupts every industry, we're proud to be leading the way for drug development. https://t.co/TlpGKbV4mn
0
3
3
Formation Bio welcomes our first class of Entrepreneurs in Residence! These dealmaking veterans will help drive pipeline growth, partnerships & BD strategy. Read more here: https://t.co/Bql1140Ajq
0
1
4
Exclusive: Ex-Pfizer CSO Mikael Dolsten joins Formation Bio to guide drug strategy — and shape how its AI makes R&D bets. https://t.co/gemHuP3Y2k
endpoints.news
Former Pfizer CSO Mikael Dolsten joins Formation Bio to lead drug-picking committee and help train AI systems, as startup aims to create AI version of veteran drug hunter's expertise.
0
1
5
Check out Part 2 of our blog series that goes "behind the scenes" of Muse, our GenAI-powered recruitment tool that streamlines patient recruitment for clinical trials. https://t.co/rYOlOq3B6s
0
0
3
At Formation Bio, we're building AI systems to accelerate and improve drug development. Our latest blog dives into Muse, our AI tool that transforms patient recruitment, creating recruitment strategy and materials in a matter of minutes. https://t.co/MIZ9yZEbZx
0
2
5